Rational Design and Comparison of Novel 99m Tc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types
Journal of Medicinal Chemistry · 2024
DOI: 10.1021/acs.jmedchem.4c00772 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medicinal Chemistry, 2024. Verfasst von Lingxin Meng und 10 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, S…. Hauptthemen laut MEDLINE: Tomography, Emission-Computed, Single-Photon, Organotechnetium Compounds. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Natural Science Foundation of China-Nuclear Technology Innovation Joint Fund, China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (Originalsprache)
Recognizing the significance of SPECT in nuclear medicine and the pivotal role of fibroblast activation protein (FAP) in cancer diagnosis and therapy, this study focuses on the development of 99mTc-labeled dimeric HF2 with high tumor uptake and image contrast. The dimeric HF2 was synthesized and radiolabeled with 99mTc in one pot using various coligands (tricine, TPPTS, EDDA, and TPPMS) to yield [99mTc]Tc-TPPTS-HF2, [99mTc]Tc-EDDA-HF2, and [99mTc]Tc-TPPMS-HF2 dimers. SPECT imaging results indicated that [99mTc]Tc-TPPTS-HF2 exhibited higher tumor uptake and tumor-to-normal tissue (T/NT) ratio than [99mTc]Tc-EDDA-HF2 and [99mTc]Tc-TPPMS-HF2. Notably, [99mTc]Tc-TPPTS-HF2 exhibited remarkable tumor accumulation and retention in HT-1080-FAP and U87-MG tumor-bearing mice, thereby surpassing the monomeric [99mTc]Tc-TPPTS-HF. Moreover, [99mTc]Tc-TPPTS-HF2 achieved acceptable T/NT ratios in the hepatocellular carcinoma patient-derived xenograft (HCC-PDX) model, which provided identifiable contrast and imaging quality. In conclusion, this study presents proof-of-concept research on 99mTc-labeled FAP inhibitor dimers for the visualization of multiple tumor types. Among these candidate compounds, [99mTc]Tc-TPPTS-HF2 showed excellent clinical potential, thereby enriching the SPECT tracer toolbox.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Vaccines for Infectious Diseases, Center for Molecular Imaging and Translational Medicine, Xiang An Biomedicine Laboratory, School of Public Health, Xiamen University, 4221-116 Xiang'An South Rd,…
- Department of Nuclear Medicine & Minnan PET Center, The First Affiliated Hospital of Xiamen University, Xiamen 361003, China.
- Theranostics and Translational Research Center, Institute of Clinical Medicine, Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College,…
ORCID-Profile: Haojun Chen, Zhide Guo
Förderung
- National Natural Science Foundation of China-Nuclear Technology Innovation Joint Fund
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
- National High-Level Hospital Clinical Research
Zitieren
APA
Meng, L., Fang, J., Zhang, J., Li, H., Xia, D., Zhuang, R., Chen, H., Huang, J., Li, Y., Zhang, X., & Guo, Z. (2024). Rational Design and Comparison of Novel 99m Tc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c00772
Vancouver
Meng L, Fang J, Zhang J, Li H, Xia D, Zhuang R, et al. Rational Design and Comparison of Novel 99m Tc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types. Journal of Medicinal Chemistry. 2024. doi:10.1021/acs.jmedchem.4c00772
BibTeX
@article{Meng2024,
author = {Meng, Lingxin and Fang, Jianyang and Zhang, Jingru and Li, Huifeng and Xia, Dongsheng and Zhuang, Rongqiang and Chen, Haojun and Huang, Jinxiong and Li, Yesen and Zhang, Xianzhong and Guo, Zhide},
title = {Rational Design and Comparison of Novel 99m Tc-Labeled FAPI Dimers for Visualization of Multiple Tumor Types},
journal = {Journal of Medicinal Chemistry},
year = {2024},
doi = {10.1021/acs.jmedchem.4c00772}
}
EUVIMED